Cargando…
Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display
Background: Extracellular vesicles (EVs) are attracting interest as a new class of drug delivery vehicles due to their intrinsic nature of biomolecular transport in the body. We previously demonstrated that EV surface modification with tissue-specific molecules accomplished targeted EV-mediated DNA...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869414/ https://www.ncbi.nlm.nih.gov/pubmed/35200409 http://dx.doi.org/10.3390/bioengineering9020056 |
_version_ | 1784656492124700672 |
---|---|
author | Komuro, Hiroaki Aminova, Shakhlo Lauro, Katherine Woldring, Daniel Harada, Masako |
author_facet | Komuro, Hiroaki Aminova, Shakhlo Lauro, Katherine Woldring, Daniel Harada, Masako |
author_sort | Komuro, Hiroaki |
collection | PubMed |
description | Background: Extracellular vesicles (EVs) are attracting interest as a new class of drug delivery vehicles due to their intrinsic nature of biomolecular transport in the body. We previously demonstrated that EV surface modification with tissue-specific molecules accomplished targeted EV-mediated DNA delivery. Methods: Here, we describe reliable methods for (i) generating EGFR tumor-targeting EVs via the display of high-affinity monobodies and (ii) in vitro measurement of EV binding using fluorescence and bioluminescence labeling. Monobodies are a well-suited class of small (10 kDa) non-antibody scaffolds derived from the human fibronectin type III (FN3) domain. Results: The recombinant protein consists of the EGFR-targeting monobody fused to the EV-binding domain of lactadherin (C1C2), enabling the monobody displayed on the surface of the EVs. In addition, the use of bioluminescence or fluorescence molecules on the EV surface allows for the assessment of EV binding to the target cells. Conclusions: In this paper, we describe methods of EV engineering to generate targeted delivery vehicles using monobodies that will have diverse applications to furnish future EV therapeutic development, including qualitative and quantitative in vitro evaluation for their binding capacity. |
format | Online Article Text |
id | pubmed-8869414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88694142022-02-25 Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display Komuro, Hiroaki Aminova, Shakhlo Lauro, Katherine Woldring, Daniel Harada, Masako Bioengineering (Basel) Article Background: Extracellular vesicles (EVs) are attracting interest as a new class of drug delivery vehicles due to their intrinsic nature of biomolecular transport in the body. We previously demonstrated that EV surface modification with tissue-specific molecules accomplished targeted EV-mediated DNA delivery. Methods: Here, we describe reliable methods for (i) generating EGFR tumor-targeting EVs via the display of high-affinity monobodies and (ii) in vitro measurement of EV binding using fluorescence and bioluminescence labeling. Monobodies are a well-suited class of small (10 kDa) non-antibody scaffolds derived from the human fibronectin type III (FN3) domain. Results: The recombinant protein consists of the EGFR-targeting monobody fused to the EV-binding domain of lactadherin (C1C2), enabling the monobody displayed on the surface of the EVs. In addition, the use of bioluminescence or fluorescence molecules on the EV surface allows for the assessment of EV binding to the target cells. Conclusions: In this paper, we describe methods of EV engineering to generate targeted delivery vehicles using monobodies that will have diverse applications to furnish future EV therapeutic development, including qualitative and quantitative in vitro evaluation for their binding capacity. MDPI 2022-01-29 /pmc/articles/PMC8869414/ /pubmed/35200409 http://dx.doi.org/10.3390/bioengineering9020056 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Komuro, Hiroaki Aminova, Shakhlo Lauro, Katherine Woldring, Daniel Harada, Masako Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display |
title | Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display |
title_full | Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display |
title_fullStr | Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display |
title_full_unstemmed | Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display |
title_short | Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display |
title_sort | design and evaluation of engineered extracellular vesicle (ev)-based targeting for egfr-overexpressing tumor cells using monobody display |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869414/ https://www.ncbi.nlm.nih.gov/pubmed/35200409 http://dx.doi.org/10.3390/bioengineering9020056 |
work_keys_str_mv | AT komurohiroaki designandevaluationofengineeredextracellularvesicleevbasedtargetingforegfroverexpressingtumorcellsusingmonobodydisplay AT aminovashakhlo designandevaluationofengineeredextracellularvesicleevbasedtargetingforegfroverexpressingtumorcellsusingmonobodydisplay AT laurokatherine designandevaluationofengineeredextracellularvesicleevbasedtargetingforegfroverexpressingtumorcellsusingmonobodydisplay AT woldringdaniel designandevaluationofengineeredextracellularvesicleevbasedtargetingforegfroverexpressingtumorcellsusingmonobodydisplay AT haradamasako designandevaluationofengineeredextracellularvesicleevbasedtargetingforegfroverexpressingtumorcellsusingmonobodydisplay |